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Selective epigenetic control of the cellular machinery is a grail of drug 
development.  The balance between HAT’s and HDAC’s activities is one way the cell 
controls what, and at when during the cellular lifecycle a gene is expressed.  Having the 
ability to lock chromatin down to the histone is a powerful tool for the treatment of 
disease states like cancer.  Presented here is a preliminary exploration of the synthesis, 
and basic testing of novel compounds that use a triazole motif as a zinc binding group in 
an attempt to gain further selectivity in inhibition over HDAC’s.   
Interest in the development of organic ligands to promote a metals activity as a 
catalyst is a broad, important field within organic chemistry.  The synthesis of select 
bidentate 1,2,4-triazole- based ligands was carried out with the intent to study and to 
direct their catalytic activities once bound to a transition-metal center. 
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1.0 Triazole based HDAC inhibition 
1.1 Introduction 
Histones are the protein scaffold that binds the DNA of a eukaryotic cell into the 
chromatin structure present in the nucleus.  The DNA is wound around the protein 
octomer in a left handed helical fashion.  How tightly the DNA is, or is not bound to the 
chromatin is a chief tool that the cell uses to regulate gene expression.
1,2
 If the DNA is 
tightly bound to the histone structure it is impossible for the cascading process of genetic 




On the molecular level the genetic material is held to the protein via non covalent 
interactions between the amine functionality of lysine residues and the base pairs within 
the DNA itself.
4
  In a normal functioning cell how tightly the DNA is bound to the 
histone is controlled by the balanced interaction between histone deacetylases (HDAC) 
and histone acetyltransferase (HAT), these two classes of enzymes deacylate or acylate 
the side chain amine respectively. (Figure 1)   
This chemical transformation dictates the ability of the amine to hydrogen bond 
with the DNA.  If the HDAC is inhibited from performing its normal cellular function 
DNA transcription is up regulated in the cell.  This up regulation speeds up cellular 
processes and triggers apoptosis.  This cascade effect is one of the focuses of the cancer 

















The aim of this project was to build upon the success of previous histone HDACi 
drugs.  These drugs though they are effective suffer from being easily metabolized and 
eliminated from the body.
5
  Along with this obvious obstacle there is a second issue of 
these compounds having cross activity for all of the classes of HDAC’s 
5,8-12
  the problem 
of selectivity has previously been approached from the hydrophobic head element of the 
molecule.  It was thought that by changing the head element of the molecule, the ligand 
would be selective for one particular HDAC pocket versus another. This appears to be a 
valid approach due to the fact that all HDAC’s active sites contain the same zinc II 
cation.  Unfortunately this approach has neglected the differences in the linings of the 
wall inside the actual catalytic pocket.  This current successful generation of HDACi 
drugs contains a similar overall structure. (Figure 2)  This structure is made up of three 
Figure 1. Cartoon of histone DNA interaction 
macro and micro scale 
 
3 
parts.  These are the hydrophobic head, or recognition element, the linker arm, and 
finally, the zinc binding unit.
10,13
   
The development of the compounds in this project focused on improving the 
stability and selectivity in vitro of the zinc binding group
14
 (ZBG), through the use of 
various triazoles.   It was hoped that by varying the substituent on the triazole, and the 
nitrogen placement within the triazole itself the binding affinity to the zinc ion in the 
HDAC pocket could not only be improved but also made selective. 
To limit the focus of this study and the scope of the synthesis, SAHA was chosen 
as a template molecule.  This was done as SAHA has passed clinical trials and is 
currently in use as a cancer treatment.  SAHA is well documented and offered a stable 
easily accessible scaffold structure to build from. Keeping the phenyl group as a head 
group and a straight chain alkane as the linker arm allowed for comparison of the 
different ZBG’s not only with each other but also with known molecules. 
The varied linker lengths were used to accommodate the differences in the 
triazole moiety and the hydroxamic acid moiety as a ZBG.  As well as leading to a 
possible differentiation of action on different classes of HDAC’s.  Although the HDAC’s 
have a recurring structural motif, they are not all identical, and differing depths of   




















1.2 Synthesis of 1,2,3-Triazole SAHA analogues 
The retrosynthetic analysis of the first triazole HDACI molecules begins with the triazole 
formation that employs the azide alkyne “click” reaction, a Huisgen 2+3-dipolar 
cycloaddition.
16
  (Figure 3)  This click reaction’s placement within the synthesis allowed 
for the parallel synthesis of all analogs up until the last step. Placing the diversity element 
step at the end of the synthesis provided for the rapid development of a compound 
library. The balance of the retrosynthetic analysis was based upon standard amide bonds.  
Synthesis was carried out for two initial target molecules.  Compounds numbered 
2 and 8. (Figure 4)  The synthesis was started with 1-aminohexanoic acid and 1-
aminobutanoic acid, respectively.  After the preparation of triflic azide by reported 
methods, this was used to perform the transformation of the primary amine to an azide in 
a high-yielding clean fashion.
17,18
  This crude product was then coupled to aniline using 
standard amide coupling conditions.
19
  Compounds 2 and 8 were then purified by column 
chromatography, characterized and stored.  Aliquots of each respective compound were 
then combined under standard aqueous click conditions and mild heat resulting in the 
products, compounds 3, 4, 6 and 9, 10, and 12, in high yield and excellent purity.   
Compounds 5 and 11 failed to form in any useful amount under these particular 
click conditions.  This is believed to be because of the primary amines ability to 
coordinate the copper(I) catalyst or its copper(II) precursor.  This chelation could then be 
leading to multiple side products and a very poor reaction quality overall.  An alternate 
synthetic pathway was used to complete these two remaining compounds using common 



















































Figure 8. Alternate pathway for propargyl amine based triazoles 
 
9 
All products were then purified using flash chromatography.  The TMS protecting 
groups on compounds 3 and 9 were removed using TBAF, followed by another 
purification step.  Compounds 5 and 11 were finally synthesized after the Boc protection 
group was removed from compounds 13 and 14, respectively, in 25% TFA DCM this 
deprotection also resulted in a similar purification step being required 
 
 
1.3 Preliminary biological results 
 The compounds were first screened using a fluor de lys HELA cellular extract kit 
purchased from Biomol.  These assays were set using TSA as a standard and assay 
quencher. The preliminary biological results pointed to the benefit of having a longer 
alkyl linker as well as a heteroatom connected via a methelyne or ethylene group to the 4 
position in the 1,2,3-triazole.  With this knowledge further synthesis was started 
immediately before the biological results could be duplicated. 
 
 
1.4 Further analogue development/screening 
 
Based upon the results that were received, a further lengthening of the alkyl linker 
chain was required to improve activity.  Therefore the synthesis of the two most active 
triazoles was undertaken based upon 7-aminoheptanoic acid.  This synthesis followed the 
same basic scheme as presented earlier (Figure 6) 
 
10 
Once triazoles 15 and 16 were purified, they were screened along with the more 
active compounds of the previous iteration to see if there was any indication of the type 
of selectivity in target enzymes that had been sought after.  The compounds were 
screened not only against the HELA extract but also against HDAC 1 and HDAC 6.  
These assays were chosen to represent nuclear and cytosolic HDAC’s respectively.  The 






Figure 9. Synthesis of 7-aminoheptanoic acid based analogues 
 
11 
1.5 Current Ongoing Work 
The manner in which the triazole can be best utilized as a ZBG requires not only 
that a variety of triazoles be tested, but also a variety of substitution patterns on the 
triazole ring itself must be explored.  By varying not only the region chemistry of the 
triazole ring, but also the substituent placed upon it, greater control of both the selectivity 
and efficacy should be gained.  This theory led to the adaptation of  the chemistry that 
allowed for the installation of a 1,2,4-triazole via a condensation reaction with a free 
amine and a hydrazide.
20
 (Figure 7).  This approach was pursued but in the end was 
terminated due to sluggish (48 - 72 hours), harsh (100 - 110 °C) reaction conditions and 
poor overall yield (less than 50% monitored by HPLC), with a difficult separation 
following the final step. 
These difficulties led to the current investigation of the synthetic pathway 
displayed in Figure 8.
21,22
  This work is ongoing and should prove fruitful in defining the 
role that a triazole can play in the selectivity and activity of a HDAC inhibitor as the 
chelation group.   
Along with the bench-top chemistry the effort to build a functioning model of the 
HDAC pocket and the ligand interaction therein has begun.  Using Comparative 
Molecular Field Analysis (COMFA) do develop a predictive tool, it is believed that a 












Figure 10. Attempted 1,2,4-triazole formation 
Figure 8. Current 1,2,4-triazole synthetic scheme 
 
13 
1.6 Future work 
Future investigation’s should focus on bringing the activity and selectivity of the 
inhibitors up by further decoration of the triazole coupled with modification to both 
linker length and hydrophobic head recognition units.  Investigation into coupling the 
triazole ZBG to the linker group via amide bond formation or click chemistry may be 
avenues worthy of investigation.   
This work coupled with an investigation into a model that more closely mimics 
the structure of the natural substrate of HDAC’s could lead to a better drug scaffold 
candidate.  The natural substrate, being of course, the side chain located on a lysine 
residue.  The side chain amine could be easily converted to an azide and then transformed 
to a 1,2,3-triazole once this unnatural amino acid is placed in polypeptide compound on a 
solid phase support.  This could be done using known chemistry that has already been 
exploited within our laboratory.
26,27
  This approach may also lend itself to the installation 
of interesting active cyclic polypeptides for the hydrophobic head unit. (Figure 9) 
 
Figure 9. Proposed synthetic pathways for "natural" 1,2,3-triazole-based HDACi molecules 
 
14 
2.0 1,2,4-Triazole-based ligands for catalysis 
2.1 Introduction 
1,2,3-Triazole metal complexes have been studied at length by inorganic, and 
organic chemists alike.  Biologically these compounds have been known to possess 




 Meanwhile the investigations 
of inorganic chemists have focused mainly on the structure and crystal formation of the 
metal ligand complexes followed with some attention in the carbene formation and 
insertion chemistry of these compounds.
29,30
  It must be noted though that very little 




Based upon results of the studies in our group on the activity of 1,2,4-triazole 
monodentate triazole metal center complexes the investigation of a series of bidentate 
ligands was undertaken.  This study was begun in the hopes of either providing a more 
robust oxidative system or finding a selectivity of activity for the ligand metal complex.  
The basic bidentate structure was synthesized from two readily available straightchain 
amino acids, as well as one representative biphenyl system.  A relatively fast synthetic 
approach was taken so as to lay a possible foundation for the direction of a more 
thorough directed approach to the synthesis of a tunable ligand set.   
2.2 Synthesis 
The primary amine of an alkyl or aryl compound can be condensed with a 
hydrazide and other carbon source to form a 1,2,4-triazole substituted on the 4 position. 
 
15 
The alkyl amino acid was condensed with the prepared phenyl hydrazide and                  
n, n-dimethylformamide dimethyl acetal (dmfdma). Then the acid was converted to and 
ester using Fisher esterification followed directly by the formation of the hydrazide.
32,33
  
This product was then condensed in the same manner as the first step to yield the final 
product after purification.  This synthetic sequence was carried out in a linear stepwise 
manner with minimal purification until the final step. (Figure 10)  The overall yields were 
low, but this was of little interest at this time due to the focus on characterization of the 
ligand’s activity once it was complexed with a metal center.  
The biphenyl system was constructed in a very similar end product focused 
manner.  The esterification and hydrazide formation and triazole condensation took place 
in a single pot with only the solvent being stripped off in between steps.  The mono 
triazole compound was crashed out of solution using hot ethyl acetate.  This solid was 
pure enough to move on to the third step which was a Suzuki coupling.  This synthetic 
scheme hinges upon the Suzuki coupling of the two aromatic rings.  This key step to the 
synthesis was found to not be as robust while varying ring placement of the already 
installed triazole as compared to the halogen.  The coupling of the meta and ortho 
halogen with the boronic acid stalled with very little product formation.  This could not 
be overcome by prolonged reaction time, up to 7 days, elevated temperature, reflux, or a 
change in the ligation of the palladium catalyst bid(dibenzylideneacetone) palladium (II), 
(Pd(dba)2) to Palladium tetrakis ( Pd(PPh3)4), and a combination of the two catalysts.  It is 
the authors belief that the combination of electronic effect of the triazole ring placement 
along with the steric restrictions of the bulky 4-substitued triazole ring that are causing 
the failure of the normally reliable Suzuki coupling reaction. 
 
16 
Complexations of these compounds were carried out in THF at elevated 
temperature overnight, with copper (II) nitrate, and iron (III) chloride.  The equivalencies 
of metals were varied from a 1:1 ratio to a 2:1 ratio of metal: ligand respectively.  This 
was done due to the fact it was unknown at the time if the ligand’s two triazole centers 
would bind a single metal center or possibly bridge two metal centers.  (Figure 3.3)  The 
qualitative analysis of the supernatant after the complexed ligand/metal structure crashed 
out showed that the ligand preferentially bound one metal center.  The metal ligand 
complex once filtered from the supernatant was dried and screened for oxidative 
properties.  The ligands were also chelated and studied directly for their ability to act as 
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2.3 Screening and Data collection 
 The bidentate ligands were screened against cyclooctane in the presence of 
hydrogen peroxide to judge their oxidative activity.  The ligandmetal complex was 
combined with solvent, substrate and oxidant.  This reaction then was monitored by gas 
chromatography mass spectrometry (GCMS) at two time points using method 2.  Each 
experiment was run in duplicate using standardized conditions and the average 
conversion to the ketone is reported here.   The reaction conditions and order of addition 




Table 1 Standard catalyst screening reaction conditions 
 
Catalyst : Substrate : Peroxide 0.05 : 1 : 5  
Morality 0.4 M 
Solvent CH3CN 
Time  1 h /12 h 




This data is not entirely unexpected nor is it terribly encouraging as far as the 
pursuit of this particular family of ligands for oxidative chemistry.  The small 
discrepancy between the complex that was exposed to excess metal, and those exposed to 
an equimolar amount of metal could be explained by the fact that not all of the excess 
metal was washed away when the complex was filtered from the complexation solution.   
 The next set of reactions that these ligands were tested for activity in was the 2 + 
3 cycloaddition between and azide and alkyne referred to as click chemistry.  The ligands 
were compared to other known ligands that expedite  this reaction
34,35
.  The reactions 
were run at optimized conditions developed in our lab (Figure 10), and conversion was 
monitored via gcms using method 1 at three time points or 10 minutes, 30 minutes and 1 









Table 2. Bidentate ligand oxidative activity test. 


















































Table 3. Bidentate ligand click chemistry activity 
Ligand % conversion 
 
10 min 66.18 
30 min 83.71 
1 h. 85.63 
 
10 min 61.05 
30 min >95 
1 h. >95 
 
10 min 21.49 
30 min 53.04 
1 h. 66.92 
No ligand (control) 
10 min <5 
30 min 14.19 





2.4 Conclusion and proposed work 
 The small library of bidentate ligands that have been synthesized above show 
some promise as reaction direction catalysts and as a possible addition to speed hindered 
or sluggish click reactions.  The lack of oxidative activity may prove a benefit as this type 
of ligand/catalyst could be used in a reaction that is typically tolerant of many functional 
groups.   
It should be noted that typical click reaction conditions are also conducive to the 
formation of Glaser products.  Both reactions require a base, a copper(I) salt, and an 
alkyne in a slightly oxidative environment.
36
  These ligands should be screened to see if 
they support or impede Glaser reactions under conditions that have been optimized for 
the alkyne alkyne coupling.   
The affect of the length of the alkyl linker between triazoles could be investigated.  
If the linker is made longer will the ligand become bridging?  Or if the linker length is set 
much shorter will the ligand become monodentate?  Finally, to truly answer these 
questions and the structure of the active complex a crystal structure may be needed. 
With the work that has been done, is ongoing, and has been proposed on the 
synthesis and characterization of the bidentate 1,2,4 triazoles it is this authors belief that a 
useful first-generation catalyst for synthetic purposes can be developed in a rather 










List of Abbreviations 
ACN: acetonitrile 
MeCN: acetonitrile 
DMF: N, N-dimethylformamide 
DMFDMA: N, N-dimethylformamide dimethyl acetal 
TFA: trifluroacetic acid 
HDAC: histone deacetylase 
HAT: histone acetyltransferase 
GCMS: gas chromatography mass spectrometry 
EtOAc: ethyl acetate 
EDTA: ethylenediaminetetraacetic acid 
AcOH: acetic acid 
DCM: dichloromethane 
BOC: tert-butyl carbamate 
FMOC: 9-Fluorenylmethyl carbamate 
MeOH: methanol 
TMS: trimethylsilane 
SAHA: suberoylanilide hydroxamic acid 
Tf: trifluoromethanesulfonyl 
HOBT: N-hydroxybenzotriazole-H2O 





HPLC purity was measured using Beckman Coulter HPLC System Sold series 126 
solvent module and System Sold 168 detector, fitted with Varian Microsorb MV 100-5 
C8 250 x 4.6mm column.  
Method 1: Mobile phase: A= 0.1%TFA water, B=MeCN, 0 - 1min 5%B; 1 - 5.5min 
5%B→95%B; 5.5min - 10min 95%B; 10min - 12min 95%B→5%B, flow rate = 
1mL/min.; run time = 12 min. 
All NMR spectra were collected on a Varian Mercury 300 MHz instrument.  The spectra 
were then worked up using Mestrenova software.  Infrared spectroscopy taken on a Win 
Bomen FTIR instrument. 
All mass spectrometry was perfomed on a Jeoll AccuTOF DART instrument. 
6-azidohexanoic acid (1) 
 
6-Aminohexanoic acid (1.08g, 9.195 mmol) was combined with sodium bicarbonate 
(2.75 g, 32.8 mmol), and copper(II)sulfate pentahydrate (161 mg, 0.656 mmol) then 
dissolved in 100 mL of water.  The reaction was cooled to 0 ºC.  Triflic azide (24.5 mL, 
24.5mmol) was slowly added along with 15 mL of MeOH.  The reaction was allowed to 
warm to room temperature slowly and then run for 18 h.  MeOH was removed under 
vacuum, EtOAc (15 mL) was added, and the biphasic solution was then brought to a pH 
of 2 with 1M HCl.  Organic layer was collected and aqueous layer was then washed and 
 
26 
additional two times with EtOAc.  Organic layers were combined, and dried over 
anhydrous sodium sulfate.  Then organics were filtered and solvent was removed.  
Product was collected as clear crystalline solid 
1H NMR (300 MHz, CDCl3) δ 3.18 (t, 2H), 2.22 (t, 2H), 1.52 (m, 4H), 1.3 (m, 2H), IR 
(neat) 3189, 2944, 2869, 2099, 1699 cm
-1 
LRMS (Accutof/dart) m/e 158.09451 [(M+H) 
+, calcd for C6H13N3O2 158.09295] 
4-azidobutanoic acid (7) 
 
4-Aminobutanoic acid (1.12 g, 10.9 mmol) was prepared in the same manner as 6-
azidohexanoic acid.  4-azidobutanoic acid was recovered as a clear crystalline solid. 
NMR (300 MHz, CDCl3) δ 3.25 (t, 2H), 2.38 (t, 2H), 1.87 (m, 2H), IR (neat) 3068, 2944, 
2103, 1709 cm
-1 
LRMS (Accutof/dart) m/e 130.05929 [(M+H) +, calcd for C4H8N3O2 
129.05383] 
6-azido-N-phenylhexanamide (2)  
 
6-Azidohexanoic acid (353 mg, 2.25 mmol), DCC (463mg, 2.25 mmol), and HOBT 
monohydrate (346 mg, 2.25 mmol) dissolved in DMF (3 mL), and DCM (10 mL).  This 
solution was stirred at room temperature for 2 h.  The resulting suspension was then 
filtered into a solution of aniline (0.205 mL, 2.25 mmol), triethylamine (0.630 mL, 4.49 
mmol) and DCM (10 mL).  The reaction was then allowed to stir for 8 h. at room 
 
27 
temperature.  DCM was removed under vacuum the resultant heavy oil was diluted with 
EtOAc (10 mL).  The organic was washed with saturated sodium bicarbonate solution.  
The organics were then collected, combined and dried with anhydrous sodium sulfate.  
The solvent was removed and the crude product was loaded on silica gel.  The column 
was eluted with 7:1 hexanes: EtOAc.   6-Azido-N-phenylhexanamide (348 mg, 1.50 




4-Azidobutanoic acid (429 mg, 3.32 mmol) was prepared in the same way as 6-azido-n-
phenylhexanamide.  After flash column chromatography, 4:1 hexanes: EtOAc eluent 4-
azido-n-phenylbutanamide (363 mg, 1.78 mmol) 53.5% yield was recovered as a white 
solid.  
 
Standard Aqueous Click Conditions for formation of 1,2,3 triazole 
compounds. 
A single equivalent of the azido compound was weighed into a vessel.  1.0 eq. of 1 M 
sodium ascorbate was added followed by 0.1 eq. of 0.5 M copper sulfate pentahydrate, 
and 2.0 eq. 2.5 M ammonium carbonate.  An equal volume of THF was then added to the 
vessel followed by 1.1 eq of alkyne.  A magnetic stir bar was added and the reaction 
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mixture was capped and warmed to 60 ºC overnight while stirring.  The reaction was then 
cooled to room temperature, and filtered through celite.  The filtrate was then diluted with 
equal volumes of water and EtOAc.  The aqueous layer was with EtOAc.  The organic 
layers were collected and dried over anhydrous sodium sulfate.  The extract was then 
filtered and solvent was stripped under vacuum.  The resultant crude product was TLC’d 
and if further purification was required it was done so via flash chromatography, over 
silica gel.  
N-phenyl-6-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)hexanamide (3) 
 
6-azido-N-phenylhexanamide (100 mg, 0.431 mmol) was combined with TMS-alkyne 
(0.067 mL, 0.474 mmol) under standard click conditions. The crude product extract was 
taken up in THF, followed by the addition of 1 M TBAF solution in THF.  This solution 
was allowed to stir for 2 h.  After the removal of the TMS group was confirmed by TLC, 
the solvent was stripped under vacuum.  This crude oil was then columned clean over 
silica gel with 100% EtOAc as eluent. 
H
1
 NMR (300 MHz, CD3OD) δ 8.29 (s, 1H), 7.53 (m, 3H), 7.27 (m, 2H), 7.03 (m, 1H), 
4.32 (m, 2H) 2.31 (m,2H) 1.87 (m, 4H) 1.97 (m, 2H).1.32 (m, 2H) HRMS: 
(AccuTOF/dart) m/e 259.15596 [(M+H)+, calcd for C14H19N4O1 259.15589] HPLC: 
(Method 1): retention time 7.989 min 
 
29 
N-phenyl-4-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl) butanamide (9) 
 
4-Azido-N-phenylbutanamide (100 mg, 0.490 mmol) was combined with TMS-alkyne 
(0.072 mL, 0.539 mmol) under standard click conditions the crude product extract was 
taken up in THF, followed by the addition of 1 M TBAF solution in THF.  This solution 
was allowed to stir for 2 h.  After the removal of the TMS group was confirmed by TLC, 
the solvent was stripped under vacuum.  This crude oil was then columned clean over 
silica gel this crude oil was then columned clean over silica gel with 100% EtOAc as 
eluent.  H
1
 NMR (300 MHz, CD3OD) δ 7.8 (m, 7H), 4.48 (s, 2H), 2.29 (m, 2H), 1.19 (m, 
4H), HRMS: (AccuTOF/dart) m/e 231.12453 [(M+H) +, calcd for C12H15N4O1 




6-Azido-N-phenylhexanamide (100mg, 0.431 mmol) was combined with propargyl 
alcohol (0.028 mL 0.474 mmol) under standard click conditions.  Crude product was 
purified via flash chromatography through silica gel.  Solvent gradient was taken from 





 NMR (300 MHz, CD3OD) δ 7.90 (s, 1H), 7.53 (d, 2H), 7.26 (m, 2H), 7.08 (m, 1H), 
4.65 (s, 2H) 4.42 (t, 2H) 2.37 (t, 2H) 1.97 (m, 2H) 1.75 (m, 2H) 1.41 (m, 2H)  HRMS: 
(AccuTOF/dart) m/e 289.16475 [(M+H)+, calcd for C15H21N4O2 289.16645]  HPLC: 
(Method 1) retention time 7.519 min. 
4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-N-phenylbutanamide (10) 
 
4-Azido-N-phenylbutanamide (100mg, 0.490 mmol) was combined with propargyl 
alcohol (0.032 mL, 0.539 mmol) under standard click conditions.  Crude product was 
purified via flash chromatography through silica gel.  Solvent gradient was taken from 
8:1 EtOAc: MeOH to 4:1 EtOAc: MeOH.  91 mg of the product was collected as an off 
white solid, 71% yield.  H
1
 NMR (300 MHz, CD3OD) δ 8.29 (s, 1H), 7.38 (m, 5H), 4.32 
(s, 2H), 2.31 (m, 2H), 1.33 (m, 4H) HPLC (Method 1) retention time 7.519 min.  HRMS: 




6-Azido-N-phenylhexanamide (100 mg, 0.431 mmol) was combined with tert-butyl prop-
2-ynylcarbamate (84mg, 0.474 mmol) under standard click conditions.  The crude extract 
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was taken up in DCM/TFA and allowed to stir until the removal of the Boc protecting 
group was verified via TLC.  This compound required no further purification, 101 mg of 
product was collected as brown heavy oil giving an 82% yield.  H
1
 NMR (300 MHz, 
CD3OD) δ 7.83 (s, 1H), 7.51 (d, 2H), 7.26 (m, 2H), 7.07 (t, 1H), 4.40 (s, 2H) 3.85 (b, 2H) 
2.36 (t, 2H) 1.97 (m, 2H) 1.75 (m, 2H) 1.40 (m, 2H)  HPLC (Method 1) retention time 




4-azido-N-phenylbutanamide (100 mg, 0.490 mmol) was combined with propargyl 
alcohol (0.032 mL, 0.539 mmol) under standard click conditions.  The Boc protected 
intermediate was purified via flash chromatography over silica gel using a combination of 
EtOAc: MeOH.  The intermediate was then taken up in DCM/TFA and allowed to stir 
until the removal of the Boc protecting group was verified via TLC.  The solvent was 
stripped resulting in the 61 mg, 34% yield of the product being recovered as heavy brown 
oil.  (300 MHz, CD3OD) δ 8.07 (s, 1H), 7.51 (m, 2H), 7.27 (t, 2H), 7.07 (d, 1H), 4.50 (t, 
2H) 4.21 (d, 2H) 3.31 (e, 2H) 2.32 (m, 4H)  HPLC(Method 1) retention time 6.953min  






6-Azido-N-phenylhexanamide (100 mg, 0.431 mmol) was combined with but-3-yn-1-ol 
(0.036 mL, 0.474 mmol) under standard click conditions.  This product required no 
further purification after extraction.  (300 MHz, CD3OD) δ 7.76 (s, 1H) 7.52 (d, 2H) 7.27 
(m 2H) 7.08 (m, 1H) 4.36 (t, 2H) 3.78 (t, 2H) 2.87 (t, 2H) 2.35 (t, 2H) 1.94 (m, 2H) 1.72 
(m, 2H) 1.38 (m, 2H) HPLC (Method 1) retention time 7.511min   
HRMS (AccuTOF/dart) m/e 303.18143 [(M+H) +, calcd for C16H23N4O2 303.18210] 
Tert-butyl prop-2-ynylcarbamate (Boc-propargyl amine) 
 
Propargyl amine (0.300 mL, 4.37 mmol) was dissolved in a flask with EtOAc (30 mL).  
Boc-anhydride (1.05 g, 4.81 mmol) was added to reaction along with a magnetic stir bar.  
Then 2.5 M NaOH (30mL) was poured into the reaction and it was allowed to stir for 6 
hours at room temperature while being monitored via TLC.  When completed, the 
reaction was cooled to 0 ºC in and ice water bath, and the pH was adjusted to 2 with 1 M 
HCl.  The reaction was extracted with EtOAc.  The organics were dried over anhydrous 
sodium sulfate, filtered and solvent stripped under vacuum.  The product was used 




trifluoromethanesulfonyl azide (triflic azide) 
 
Sodium azide (6.23 g, 95.8 mmol) was dissolved in 100 mL of water while stirring.  This 
solution was cooled to 0 ºC.  Trifluoromethanesulfonic anhydride (8.00 mL, 63.9 mmol) 
was diluted in toluene (30 mL).  This was then dripped slowly into stirring azide solution.  
The biphasic reaction mixture was allowed to stir vigorously for 3 h.   The organic layer 
was extracted from the reaction mixture and diluted further with toluene to give an 
approximate molarity of 1.  The product was used as was with out further purification or 
characterization. 
(9H-fluoren-9-yl) methyl 7-oxo-7-(phenylamino)heptylcarbamate 
 
Fmocaminoheptanoic acid (521 mg, 1.40mmol) coupled with aniline (0.127 mL, 1.40 
mmol) under standard DCC amide coupling conditions.  The reaction was allowed to run 
for 8 h. then  diluted with DCM (20 mL) the organic layer was extracted 2 times with 2 
M NaOH, followed by 1 1 M HCl wash. LRMS (AccuTOF/dart) m/e 443.23682 [(M+H) 






(9H-Fluoren-9-yl)methyl7-oxo-7-(phenylamino)heptylcarbamate crude was taken up in 
dmf (10 ml).  Piperdine (0.5 mL) added and stirred for 2 hours.  The solvent was stripped 
under vacuum.  The remaining residue was prepared in the same way as 6-azido-N-
phenylhexanamide.  This product was used without further purification or 
characterization. 
7-(4-(2-hydroxyethyl)-1H-1, 2, 3-triazol-1-yl)-N-phenylheptanamide (16) 
 
7-Azido-N-phenylheptanamide, (70 mg, 0.284 mmol) was reacted with but-3-yn-1-ol (20 
mg, 0.285 mmol) under standard click conditions.  The extract was purified via flash 
chromatography.  Product was collected as a white solid 50 mg, 55.7% yield.  (300 MHz, 
CD3OD) δ 7.74 (s, 1H) 7.52 (d, 2H) 7.39 (s, 1H) 7.27 (m, 2H) 7.07 (t, 1H) 4.30 (t, 2H) 
3.93 (s, 2H) 2.94 (dd, 2H) 2.30 (t, 2H) 1.87 (m, 2H) 1.69 (m, 2H) 1.34 (m, 4H)  HPLC 




7-(4-(hydroxymethyl)-1H-1, 2, 3-triazol-1-yl)-N-phenylheptanamide  
 
7-Azido-N-phenylheptanamide, (70 mg, 0.28 mmol) was reacted with propargyl alcohol 
(16 mg, 0.29 mmol) under standard click conditions.  The extract was treated with flash 
column chromatography which resulted in the product as a white solid, 35 mg, 40.8% 
yield.  (300 MHz, CD3OD) δ 7.97 (s, 1H) 7.54 (m, 2H) 7.29 (t, 2H) 7.08 (m, 1H) 4.70 (b, 
1H) 4.41 (t, 2H) 3.32 (m, 2H) 2.36 (t, 2H) 2.20 (m, 2H) 2.03 (m, 2H) 1.39 (m, 4H) HPLC 
(Method 1) retention time 7.653min  
methyl 4-iodobenzoate 
 
4-Iodobenzoic acid (2.00 g, 8.06 mmol) dissolved in 10% H2SO4 / MeOH, reflux 
condenser was affixed and reaction was brought to reflux for 8 h.  The MeOH was 
stripped off under vacuum and the residue was brought back up in EtOAc (25 mL).  This 
solution was washed 2 times with 1 M NaOH (15 mL).  The organic layer was collected, 
dried over anhydrous sodium sulfate, filtered and then concentrated, 1.89g 89.6% yield  








Methyl 4-iodobenzoate (1.89 g, 7.22 mmol) taken up in MeOH, hydrazine monohydrate 
added (18.05 mmol).  Reaction fitted with condenser and brought to reflux.  Reaction 
allowed to stir for 24 hours, then cooled to room temperature and solvent stripped.  
Product was recovered as a white solid and used without further purification.  All spectra 





4-Iodobenzohydrazide (656.4 mg, 2.504 mmol) combined with dmfdma (0.332 mL, 
2.504 mmol) in toluene (30 mL) and brought to 80 °C for 2 h.  Then benzyl amine (0.274 
mL, 2.504 mmol) added along with 0.1 mL AcOH.  The reaction was allowed to stir at 
elevated temperature for a total reaction time of 24 h.  The toluene was removed under 
vacuum and then the resultant oil was taken up in EtOAc.  This solution was chilled to     
-30 °C and then filtered.  The solid was washed with cold EtOAc and hexanes.  No 
further purification was required 471.2 mg of white solid was recovered for a 54.0% 
yield.  (300 MHz, CD3OD) δ 8.19(s, 1H) 7.31 (m, 9H) 5.19 (s, 2H). HRMS 




Methyl 4'-(4-benzyl-4H-1,2,4-triazol-3-yl) biphenyl-4-carboxylate  
 
4-Benzyl-3-(4-iodophenyl)-4H-1,2,4-triazole (200mg, 0.554 mmol) combined with 4-
boronobenzoic acid (101 mg, .609 mmol), potassium carbonate (153 mg, 1.11 mmol) and 
Pd(DBA)2 (32 mg, .055 mmol) in dmf (6 ml) and water (1 mL).  The reaction was then 
warmed to 90°C for 24 h.  At this time TLC showed complete conversion.  The solvent 
was removed under vacuum and then immediately placed under standard Fischer 
esterification conditions to form the methyl ester.  The MeOH was removed under 
vacuum and product was purified via flash column chromatography.  100 mg of white 
solid was recovered providing a 49.0% yield over both steps.  Alternatively, product was 
collected in reasonable purity by crashing the product out of hot DCM by layering it with 
cold hexanes, after the esterification reaction was extracted with 1 M NaOH.  LRMS 
(AccuTOF/dart) m/e 370.14566 [(M+H) +, calcd for C23H20N3O2 370.15555] 
4, 4’-bis (4-benzyl-4H-1,2,4-triazol-3-yl) biphenyl 
 
Methyl 4'-(4-benzyl-4H-1,2,4-triazol-3-yl)biphenyl-4-carboxylate (370 mg, 1.00 mmol) 
taken up in MeOH, then hydrazine monohydrate (0.121 mL, 2.50 mmol) added and 
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reaction brought to reflux for 24 h.  MeOH stripped off of reaction and then residue 
purified via flash chromatography using 6:1 EtOAc: Hexanes as eluent.  The product was 
taken on without further characterization beyond TLC.  Hydrazide (277 mg) combined 
with dmfdma (0.108 mL, 0.899 mmol) in toluene (10 mL) then brought to 80 °C for 2 h.  
Benzyl amine (0.109 mL, 0.899 mmol) and AcOH (0.10 mL) added to the reaction 
mixture.  The reaction was then allowed to run for an additional 24 h.  Solvent was 
removed from reaction and the residue was purified via column chromatography yielding 
159 mg of off white solid (45% yield). .  (300 MHz, CD3OD) δ 8.18 (s, 1H) 8.04 (s, 1H) 
7.82 (m 2H) 7.57 (m, 6H) 7.30 (m, 6H) 7.09 (m, 2H) 2.93 (s, 4H) HRMS 




Methyl benzoate (17.54 g, 128.82 mmol) taken up in MeOH (35mL).  Hydrazine 
monohydrate (15.60 ml, 322.1 mmol) added over 5 minutes.  Reaction fixed with reflux 
condenser and brought to reflux for 48 h.  The reaction was stripped of solvent and then 
re-dissolved in MeOH and brought to dryness under vacuum 3 more times.  The resultant 
17.44 g of white powder 99.4% yield, required no further purification and all spectra 





Methyl 4-(3-phenyl-4H-1, 2, 4-triazol-4-yl) butanoate 
 
Benzohydrazide (467 mg, 3.45 mmol) combined with dmfdma (0.515 mL, 4.31 mmol) in 
toluene (10 mL).  The reaction was then warmed to 80 °C for 2 h.  Then 4-aminobutanoic 
acid (566 mg, 4.31 mmol) was added along with AcOH (0.10 mL)  and the reaction 
allowed to run for another 24 h.  The solvent was removed from the reaction and the 
crude was taken up in 10% H2SO4 / MeOH (15 mL) and refluxed for 12 h.  The MeOH 
was stripped off of the reaction, and crude was dissolved in DCM and washed with 
saturated sodium bicarbonate solution.  The organic was collected and dried over 
anhydrous sodium sulfate, filtered and solvent removed leaving light brown oil. LRMS 
(AccuTOF/dart) m/e 246.13103 [(M+H) +, calcd for C13H16N3O2 246.12425] 
Methyl 6-(3-phenyl-4H-1,2,4-triazol-4-yl) hexanoate 
 
Benzohydrazide (754 mg, 5.54 mmol) combined with dmfdma (0.794 mL, 6.65 mmol) in 
toluene (10 mL).  The reaction was then warmed to 80 °C for 2 h.  Then 6-
aminohexanoic acid (871 mg, 6.65 mmol) was added along with AcOH (0.10 mL) and 
the reaction allowed to run for another 24 h.  The solvent was removed from the reaction 
and the crude was taken up in 10% H2SO4 / MeOH (15 mL) and refluxed for 12 h.  The 
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MeOH was stripped off of the reaction, and crude was dissolved in DCM and washed 
with saturated sodium bicarbonate solution.  The organic was collected and dried over 
anhydrous sodium sulfate, filtered and solvent removed leaving light brown oil. LRMS 
(AccuTOF/dart) m/e 274.16029 [(M+H) +, calcd for C15H20N3O2 274.15555] 
4-benzyl-3-(3-(3-phenyl-4H-1,2,4-triazol-4-yl) propyl)-4H-1,2,4-triazole 
 
Methyl 4-(3-phenyl-4H-1,2,4-triazol-4-yl) butanoate crude (500 mg,) dissolved in 3% 
hydrazine/MeOH (15 mL) and brought to a reflux for 24 h.  Reaction monitored until 
found complete by TLC.  The solvent was then stripped from the reaction.  The crude 
residue was dissolved in toluene (10 mL) followed by the addition of dmfdma (0.10 mL).  
The reaction was then warmed to 80°C for 2 h.  Then benzyl amine (0.10mL) was added 
along with AcOH (0.10 mL) and reaction was allowed to reflux for a total of 24 h.  The 
solvent was removed under vacuum and the crude oil was purified via flash 
chromatography.  Product collected as light brown oil (433 mg, 36.4% yield over all 
steps).  (300 MHz, CD3OD) δ 8.50 (m, 2H) 7.33 (m, 10H) 5.20 (s, 2H) 4.13 (t, 2H) 2.43 





Methyl 6-(3-phenyl-4H-1,2,4-triazol-4-yl) hexanoate crude (675 mg,) dissolved in 3% 
hydrazine/MeOH (15 mL) and brought to a reflux for 24 h.  Reaction monitored until 
found complete by TLC.  The solvent was then stripped from the reaction.  The crude 
residue was dissolved in toluene (10 mL) followed by the addition of dmfdma (0.10 mL).  
The reaction was then warmed to 80 °C for 2 h.  Then benzyl amine (0.10 mL) was added 
along with AcOH (0.10 mL) and reaction was allowed to reflux for a total of 24 h.  The 
solvent was removed under vacuum and the crude oil was purified via flash 
chromatography.  Product collected as light brown oil (412 mg, 16.6% yield over all 
steps).  (300 MHz, CD3OD) δ 8.50 (m, 2H) 7.32 (m, 10H) 5.18 (s, 2H) 4.02 (d, 2H) 2.57 
(d, 2H) 1.34 (m, 4H) 
Standard Ligand Complexation Procedure 
Ligand (1 eq.) dissolved in THF (0.08 M).  Metal added to solution (1 eq.) and solution 
warmed to 60 °C for a minimum of 8 h.  Once all ligand was consumed via TLC the 
reaction was cooled to room temperature and transferred to centrifuge tube.  The reaction 
was centrifuged for 5 minutes.  Then supernatant was removed and the pellet was rinsed 
with aliquots of THF followed by subsequent centrifugation.  The solid metal complex 
was collected and dried.  For the qualitative test for bridging of ligands the same 




All GCMS data collected on a Hewlett Packard 6890 series GC system fitted with a 
Agilent 19091S-433E column, coupled to a Hewlett Packard 5973 mass selective 
detector. 
Method 1 split injection, gas flow of 0.8mL/min.  Initial temperature of 35° C, ramp 5° 
C/min to 75 °C, ramp 25° C/min to 250 °C hold 2 min. 
Method 2 split injection, gas flow of 0.8 mL/ min.  Initial temperature of 35 °C. ramp      
1 °C/ min to 40 °C, ramp 5 °C/ min to 55° C, ramp 1 °C/ min to 60 ° C, ramp 5 °C/ min 
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